Cargando…

Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018)

OBJECTIVE: To analyse the susceptibility to ceftolozane-tazobactam and comparators in Enterobacterales and Pseudomonas aeruginosa isolates recovered from intraabdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream infection (BSI) in the SMART (Study for Monitoring Antimicrobial Resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Cantón, Rafael, Loza, Elena, Arcay, Ricardo M., Cercenado, Emilia, Castillo, Francisco Javier, Cisterna, Ramón, Gálvez-Benítez, Lidia, Romo, Fernando González, Hernández-Cabezas, Alicia, Rodríguez-Lozano, Jesús, Suárez-Barrenechea, Ana Isabel, Tubau, Fe, Díaz-Regañón, Jazmín, López-Mendoza, Diego
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Quimioterapia 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179940/
https://www.ncbi.nlm.nih.gov/pubmed/33645948
http://dx.doi.org/10.37201/req/019.2021
_version_ 1783703894888546304
author Cantón, Rafael
Loza, Elena
Arcay, Ricardo M.
Cercenado, Emilia
Castillo, Francisco Javier
Cisterna, Ramón
Gálvez-Benítez, Lidia
Romo, Fernando González
Hernández-Cabezas, Alicia
Rodríguez-Lozano, Jesús
Suárez-Barrenechea, Ana Isabel
Tubau, Fe
Díaz-Regañón, Jazmín
López-Mendoza, Diego
author_facet Cantón, Rafael
Loza, Elena
Arcay, Ricardo M.
Cercenado, Emilia
Castillo, Francisco Javier
Cisterna, Ramón
Gálvez-Benítez, Lidia
Romo, Fernando González
Hernández-Cabezas, Alicia
Rodríguez-Lozano, Jesús
Suárez-Barrenechea, Ana Isabel
Tubau, Fe
Díaz-Regañón, Jazmín
López-Mendoza, Diego
author_sort Cantón, Rafael
collection PubMed
description OBJECTIVE: To analyse the susceptibility to ceftolozane-tazobactam and comparators in Enterobacterales and Pseudomonas aeruginosa isolates recovered from intraabdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream infection (BSI) in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study. METHODS: . The susceptibility of 5,351 isolates collected in 11 Spanish hospitals (2016-2018) were analysed (EUCAST-2020 criteria) by broth microdilution and were phenotypically studied for the presence of extended-spectrum beta-lactamases (ESBL). Ceftolozane-tazobactam and/or carbapenem resistant isolates were genetically characterized for ESBL and carbapenemases. RESULTS: Escherichia coli was the most frequent pathogen (49.3% IAI, 54.9% UTI, 16.7% RTI and 50% BSI), followed by Klebsiella pneumoniae (11.9%, 19.1%, 13.1% and 15.4%, respectively). P. aeruginosa was isolated in 9.3%, 5.6%, 32% and 9%, respectively. The frequency of isolates with ESBLs (2016-2017) was: 30.5% K. pneumoniae, 8.6% E. coli, 2.3% Klebsiella oxytoca and 0.7% Proteus mirabilis. Ceftolozane-tazobactam was very active against non-ESBL-(99.3% susceptible) and ESBL-(95.2%) producing E. coli being less active against K. pneumoniae (98% and 43.1%, respectively) isolates. CTX-M-15 was the most prevalent ESBL in E. coli (27.5%) and K. pneumoniae (51.9%) frequently associated with OXA-48-like carbapenemase. Overall, 93% of P. aeruginosa isolates were susceptible to ceftolozane-tazobactam, preserving this activity (>75%) in isolates resistant to other beta-lactams except in those resistant to meropenen or ceftazidime-avibactam. GES-5, PER-1, VIM-1/2 were the most prevalent enzymes in isolates resistant to ceftolozane-tazobactam. CONCLUSIONS: Ceftolozane-tazobactam showed high activity rates against isolates recovered in the SMART study although it was affected in K. pneumoniae and P. aeruginosa isolates with ESBL and/or carbapenemases.
format Online
Article
Text
id pubmed-8179940
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Sociedad Española de Quimioterapia
record_format MEDLINE/PubMed
spelling pubmed-81799402021-06-17 Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018) Cantón, Rafael Loza, Elena Arcay, Ricardo M. Cercenado, Emilia Castillo, Francisco Javier Cisterna, Ramón Gálvez-Benítez, Lidia Romo, Fernando González Hernández-Cabezas, Alicia Rodríguez-Lozano, Jesús Suárez-Barrenechea, Ana Isabel Tubau, Fe Díaz-Regañón, Jazmín López-Mendoza, Diego Rev Esp Quimioter Original OBJECTIVE: To analyse the susceptibility to ceftolozane-tazobactam and comparators in Enterobacterales and Pseudomonas aeruginosa isolates recovered from intraabdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream infection (BSI) in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study. METHODS: . The susceptibility of 5,351 isolates collected in 11 Spanish hospitals (2016-2018) were analysed (EUCAST-2020 criteria) by broth microdilution and were phenotypically studied for the presence of extended-spectrum beta-lactamases (ESBL). Ceftolozane-tazobactam and/or carbapenem resistant isolates were genetically characterized for ESBL and carbapenemases. RESULTS: Escherichia coli was the most frequent pathogen (49.3% IAI, 54.9% UTI, 16.7% RTI and 50% BSI), followed by Klebsiella pneumoniae (11.9%, 19.1%, 13.1% and 15.4%, respectively). P. aeruginosa was isolated in 9.3%, 5.6%, 32% and 9%, respectively. The frequency of isolates with ESBLs (2016-2017) was: 30.5% K. pneumoniae, 8.6% E. coli, 2.3% Klebsiella oxytoca and 0.7% Proteus mirabilis. Ceftolozane-tazobactam was very active against non-ESBL-(99.3% susceptible) and ESBL-(95.2%) producing E. coli being less active against K. pneumoniae (98% and 43.1%, respectively) isolates. CTX-M-15 was the most prevalent ESBL in E. coli (27.5%) and K. pneumoniae (51.9%) frequently associated with OXA-48-like carbapenemase. Overall, 93% of P. aeruginosa isolates were susceptible to ceftolozane-tazobactam, preserving this activity (>75%) in isolates resistant to other beta-lactams except in those resistant to meropenen or ceftazidime-avibactam. GES-5, PER-1, VIM-1/2 were the most prevalent enzymes in isolates resistant to ceftolozane-tazobactam. CONCLUSIONS: Ceftolozane-tazobactam showed high activity rates against isolates recovered in the SMART study although it was affected in K. pneumoniae and P. aeruginosa isolates with ESBL and/or carbapenemases. Sociedad Española de Quimioterapia 2021-03-01 2021 /pmc/articles/PMC8179940/ /pubmed/33645948 http://dx.doi.org/10.37201/req/019.2021 Text en © The Author 2021 https://creativecommons.org/licenses/by-nc/4.0/Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle Original
Cantón, Rafael
Loza, Elena
Arcay, Ricardo M.
Cercenado, Emilia
Castillo, Francisco Javier
Cisterna, Ramón
Gálvez-Benítez, Lidia
Romo, Fernando González
Hernández-Cabezas, Alicia
Rodríguez-Lozano, Jesús
Suárez-Barrenechea, Ana Isabel
Tubau, Fe
Díaz-Regañón, Jazmín
López-Mendoza, Diego
Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018)
title Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018)
title_full Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018)
title_fullStr Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018)
title_full_unstemmed Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018)
title_short Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018)
title_sort antimicrobial activity of ceftolozane-tazobactam against enterobacterales and pseudomonas aeruginosa recovered during the study for monitoring antimicrobial resistance trends (smart) program in spain (2016-2018)
topic Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179940/
https://www.ncbi.nlm.nih.gov/pubmed/33645948
http://dx.doi.org/10.37201/req/019.2021
work_keys_str_mv AT cantonrafael antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018
AT lozaelena antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018
AT arcayricardom antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018
AT cercenadoemilia antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018
AT castillofranciscojavier antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018
AT cisternaramon antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018
AT galvezbenitezlidia antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018
AT romofernandogonzalez antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018
AT hernandezcabezasalicia antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018
AT rodriguezlozanojesus antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018
AT suarezbarrenecheaanaisabel antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018
AT tubaufe antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018
AT diazreganonjazmin antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018
AT lopezmendozadiego antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018
AT antimicrobialactivityofceftolozanetazobactamagainstenterobacteralesandpseudomonasaeruginosarecoveredduringthestudyformonitoringantimicrobialresistancetrendssmartprograminspain20162018